Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Asthma: Pathogenesis and Management01:20

Asthma: Pathogenesis and Management

1.5K
Asthma is a chronic pulmonary condition involving inflammation of the airways, hyper-reactivity, and reversible obstruction of the airways. This condition can significantly impact a person's quality of life, making breathing difficult and leading to distressing symptoms.
Asthma is classified as allergic and non-allergic. Allergens such as dust mites, pollen, and pet dander trigger allergic asthma, while factors like cold air, intense emotions, or exercise can induce non-allergic asthma.
1.5K
Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs01:25

Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs

2.4K
Asthma is a chronic respiratory condition for which new therapeutic avenues, including anti-inflammatory drugs like mast cell stabilizers and anti-IgE treatments, continue to be developed.
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
2.4K
Asthma-II: Pathophysiology and Classification01:26

Asthma-II: Pathophysiology and Classification

4.7K
Asthma is a prevalent chronic respiratory condition marked by inflammation and hyperresponsiveness of the airways. Its pathophysiology involves complex interactions among inflammatory pathways, immune responses, and neural mechanisms.
Additionally, environmental and genetic factors play crucial roles in determining an individual's susceptibility to asthma and the severity of their condition.
Critical processes in asthma pathophysiology include:
4.7K
Antiasthma Drugs: Inhaled Corticosteroids and Glucocorticoids01:25

Antiasthma Drugs: Inhaled Corticosteroids and Glucocorticoids

2.1K
Inhaled corticosteroids (ICS) are anti-inflammatory drugs used primarily in treating persistent asthma and providing long-term maintenance. They target the bronchial mucosa, the lining of the airways, to control inflammation, a critical factor in asthma progression and exacerbation.
ICS work through a multifaceted mechanism of action. They suppress the inflammatory response caused by the proliferation of TH cells. They also reduce the transcription of the IL-2 gene, which is involved in the...
2.1K
Asthma-IV: Diagnostic and Management01:30

Asthma-IV: Diagnostic and Management

3.4K
The diagnosis and management of asthma are comprehensive, encompassing clinical assessments, lung function tests, and pharmacological interventions. Here's an overview:
Clinical Assessment for Asthma:
This is the first step in diagnosing and managing asthma. It includes:
3.4K
Antiasthma Drugs: Leukotriene Modifiers01:19

Antiasthma Drugs: Leukotriene Modifiers

2.2K
Leukotriene modifiers, or cysteinyl leukotriene receptor antagonists, are medications used to manage chronic asthma. These agents target specific inflammatory mediators produced during arachidonic acid metabolism, an essential process in generating inflammation in the body.
Leukotriene modifiers work through two distinct mechanisms:
2.2K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Recent Developments in Monoclonal-Antibody-Based Biologic Therapy for Severe Refractory Eosinophilic Asthma.

Antibodies (Basel, Switzerland)·2025
Same author

Therapeutics and Clinical Risk Management - 20<sup>th</sup> Anniversary.

Therapeutics and clinical risk management·2025
Same author

Recent developments in the use of monoclonal antibodies targeting the type 2 cytokines for severe asthma treatment.

Advances in pharmacology (San Diego, Calif.)·2023
Same author

Molecular Biology of Eosinophils: Introduction.

Methods in molecular biology (Clifton, N.J.)·2021
Same author

Anti-IL-5 monoclonal antibodies for the treatment of asthma: an update.

Expert opinion on biological therapy·2020
Same author

Dupilumab utility in difficult-to-treat asthma.

Immunotherapy·2019

Related Experiment Video

Updated: May 6, 2026

Bronchial Thermoplasty: A Novel Therapeutic Approach to Severe Asthma
14:39

Bronchial Thermoplasty: A Novel Therapeutic Approach to Severe Asthma

Published on: November 4, 2010

34.4K

An update on biologic-based therapy in asthma.

Garry M Walsh1

  • 1Section of Immunology & Infection, Division of Applied Medicine, School of Medicine & Dentistry, Institute of Medical Sciences, University of Aberdeen, Foresterhill, Aberdeen AB25 2ZD, UK. g.m.walsh@abdn.ac.uk.

Immunotherapy
|November 6, 2013
PubMed
Summary
This summary is machine-generated.

Biologics targeting airway inflammation in asthma show promise, but effectiveness varies. Selecting patients based on asthma phenotypes and biomarkers is crucial for successful treatment with monoclonal antibodies.

More Related Videos

A Traditional Chinese Medicine Characteristic Therapy for Bronchial Asthma: Moxibustion
05:56

A Traditional Chinese Medicine Characteristic Therapy for Bronchial Asthma: Moxibustion

Published on: May 12, 2023

6.6K
Basophil Activation Test for Allergy Diagnosis
07:22

Basophil Activation Test for Allergy Diagnosis

Published on: May 31, 2021

10.0K

Related Experiment Videos

Last Updated: May 6, 2026

Bronchial Thermoplasty: A Novel Therapeutic Approach to Severe Asthma
14:39

Bronchial Thermoplasty: A Novel Therapeutic Approach to Severe Asthma

Published on: November 4, 2010

34.4K
A Traditional Chinese Medicine Characteristic Therapy for Bronchial Asthma: Moxibustion
05:56

A Traditional Chinese Medicine Characteristic Therapy for Bronchial Asthma: Moxibustion

Published on: May 12, 2023

6.6K
Basophil Activation Test for Allergy Diagnosis
07:22

Basophil Activation Test for Allergy Diagnosis

Published on: May 31, 2021

10.0K

Area of Science:

  • Immunology
  • Pulmonology
  • Pharmacology

Background:

  • Airway inflammation is central to asthma pathogenesis, but its heterogeneity complicates treatment development.
  • Biologics targeting key inflammatory mediators like IL-4, IL-5, and IL-13 have been developed for asthma.
  • Early trials of cytokine-targeted biologics yielded disappointing results in most asthma patients, unlike animal models.

Purpose of the Study:

  • To review the effectiveness of monoclonal antibody-based therapies in asthma.
  • To explore the role of patient selection and biomarkers in optimizing biologic therapy for asthma.

Main Methods:

  • Review of recent evidence on monoclonal antibody therapies for asthma.
  • Analysis of clinical trial outcomes for biologics targeting cytokines and IgE.
  • Discussion of the impact of asthma phenotypes and genetic profiling on treatment response.

Main Results:

  • Monoclonal antibody therapies, including anti-IgE (omalizumab), have shown variable efficacy in asthma patients.
  • Cytokine-targeted biologics have demonstrated limited success in broad patient populations.
  • Evidence suggests improved outcomes with anticytokine therapies in carefully selected patient groups.

Conclusions:

  • Effective use of biologic therapies in asthma hinges on identifying specific patient phenotypes.
  • Biomarkers and genetic profiling are essential for selecting patients likely to respond to targeted asthma treatments.
  • Further research is needed to refine patient stratification for monoclonal antibody-based asthma therapies.